New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024.
FDA approves 1st new drug to treat schizophrenia in more than 30 years
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo
First Novel Schizophrenia Treatment in Decades Gains FDA Approval
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of treatments that could help stabilize patients’ symptoms without the uncomfortable side effects that accompany existing antipsychotics.
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment
Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to target cholinergic receptors rather than dopamine receptors,
bovnews6h
Royalty Pharma plc (RPRX) Posted 30.07% Profit Margin Last Year—Can It Hold Up?
UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
MT Newswires on MSN9h
Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug
Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.
bovnews2d
UBS Issues Neutral Rating for Royalty Pharma plc (RPRX) Stock
On Tuesday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.71 which represents no change from the prior close of $27.71. The stock opened at $27.71 and touched a low of $27 ...
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
Bristol Myers Squibb is the century-old pharmaceutical giant that markets the oral blood thinner Eliquis in partnership with ...
stocknews2d
3 Biotech Stocks Wall Street Predicts Will Skyrocket
Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...
Crain's Chicago Business2d
Abbott tries to claw back $24.3 million from the IRS
In a federal tax court petition, Abbott rejects numerous "arbitrary, capricious and unreasonable" determinations the IRS made ...
EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
EQS-News: BRAIN Biotech AG / Key word (s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST ...
Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Most readers would already be aware that Royalty Pharma's (NASDAQ:RPRX) stock increased significantly by 6.7% over ...
Franco-Nevada Corporation: Trading At A Deep Discount To Fair Value
Despite revenue and cash flow declines, Franco-Nevada reported record margins with an 88.7% cash margin, benefiting from ...